SJS / Toxic Epidermal Necrolysis

What Is Stevens Johnson Syndrome and Toxic Epidermal Necrolysis?

Stevens Johnson syndrome and toxic epidermal necrolysis, often referred to together as SJS and TEN, represent two ends of the same rare but life threatening spectrum of severe skin reaction, most often triggered by a medication. Both conditions cause widespread death of skin cells, leading to painful blistering and extensive skin detachment.¹

Physicians classify these conditions based on how much of the body’s total skin surface becomes affected. SJS involves a smaller percentage of body surface area, TEN involves a considerably larger percentage, and an intermediate category, called SJS TEN overlap, falls between the two, reflecting the fact that these conditions exist along a single continuum of severity rather than representing entirely separate diseases.¹

Because SJS and TEN can progress with alarming speed and carry significant mortality risk, particularly the more severe TEN form, both are considered genuine medical emergencies requiring immediate hospitalization, often within a specialized burn unit equipped to manage extensive skin loss.²

SJS and TEN represent different ends of the spectrum of the same clinical entity causing severe mucocutaneous reactions, usually to drugs, characterized by intraepidermal cell death leading to blistering and epidermal sloughing.
National Center for Biotechnology Information

Symptoms

SJS and TEN typically begin with nonspecific, influenza like symptoms, including fever, sore throat, and general malaise, appearing in the days before the more characteristic skin and mucosal findings develop.¹

The hallmark skin finding is painful, spreading redness that rapidly progresses to blistering and eventual skin detachment, often described as resembling a severe burn, and this skin involvement is frequently accompanied by significant mucosal involvement affecting the mouth, eyes, and genital area in more than ninety percent of patients.¹

Eye involvement can range from relatively mild conjunctivitis to much more serious complications, including corneal damage and scarring that can threaten vision, making prompt ophthalmologic evaluation an essential part of care for anyone diagnosed with SJS or TEN.³

Causes

The large majority of SJS and TEN cases result from a severe, delayed immune reaction to a specific medication, classified medically as a type four hypersensitivity reaction, in which the immune system mistakenly triggers widespread destruction of skin cells.¹

Certain medications carry particularly high risk, including allopurinol, several anticonvulsant medications, sulfonamide antibiotics, and specific nonsteroidal anti inflammatory drugs, though a considerable range of additional medications have also been documented as occasional triggers in published case reports.⁴

Reactions typically develop within about four weeks of starting the causative medication, and less commonly, SJS and TEN can be triggered by infections or, rarely, certain vaccinations rather than a medication reaction, though drug related causes remain far more common overall.¹

Risk Factors

Genetic factors meaningfully influence individual susceptibility to SJS and TEN, and certain specific genetic markers have been strongly linked to increased risk of reaction to particular medications, particularly among people of certain ethnic backgrounds.¹

Having certain underlying medical conditions, including HIV infection and specific autoimmune diseases, has been associated with meaningfully elevated risk of developing SJS or TEN in response to a triggering medication.²

A prior personal history of SJS or TEN represents an important risk factor for future episodes, and patients who have experienced either condition are generally advised to permanently avoid the specific medication responsible, along with any chemically related drugs that could theoretically trigger a similar reaction.¹

Complications

Sepsis represents the most common serious complication during the acute phase of SJS and TEN, and infection remains the leading cause of death for patients with these conditions, reflecting the significant vulnerability created by extensive skin barrier loss.²

Mortality varies considerably based on disease severity, with SJS carrying a mortality rate of roughly one to five percent, while TEN, the more severe form, carries a considerably higher mortality rate estimated between twenty five and thirty percent.⁵

Survivors can face long term complications as well, particularly involving the eyes, where scarring can lead to chronic dryness, light sensitivity, and, in severe cases, permanent vision impairment, underscoring the importance of ongoing specialized follow up care after the acute illness resolves.³

Treatment

Immediate discontinuation of the suspected causative medication represents the single most important initial treatment step, since continued exposure allows the underlying reaction to keep progressing and worsening.²

Supportive care, similar in many respects to burn care, forms the backbone of treatment, including careful fluid and electrolyte management, nutritional support, and meticulous wound care to protect denuded skin from infection while it heals.²

Additional targeted therapies, including high dose corticosteroids, cyclosporine, and intravenous immunoglobulin, have each shown benefit in various studies, with some evidence suggesting that combination approaches may further reduce mortality risk, though treatment decisions require careful individualization based on disease severity and patient specific factors.⁶

Prevention

Because SJS and TEN are so strongly linked to specific medications, careful documentation of any prior drug reaction and strict avoidance of the responsible medication, along with related drugs, represents the most important prevention strategy for anyone who has previously experienced either condition.¹

For patients starting a new high risk medication, awareness of early warning signs, including unexplained fever, sore throat, and skin pain preceding visible rash, allows for prompt discontinuation and medical evaluation before the reaction has an opportunity to progress further.¹

Genetic testing prior to starting certain high risk medications, particularly in populations known to carry specific genetic markers associated with elevated risk, has become an increasingly important preventive tool in some clinical settings, helping to avoid prescribing especially risky medications to genetically susceptible individuals.¹

Why Visual Communication Matters for SJS and TEN

Explaining why a common medication can trigger such an extreme, body wide reaction, or why these conditions require burn unit level care despite starting as what looks like a simple rash, requires visuals that clearly convey both the underlying immune mechanism and the genuine severity of these conditions.¹

Pharmaceutical companies, hospital systems, and patient safety organizations rely on precise illustration and animation to explain the biology behind SJS and TEN and the importance of rapid recognition and treatment.

• Illustrating how immune mediated keratinocyte death leads to widespread skin detachment
• Animating the spectrum from SJS through overlap to TEN based on body surface involvement
• Explaining high risk medications and early warning signs for patient safety education
• Visualizing the SCORTEN scoring system used to assess mortality risk
• Supporting clinical training on burn unit level supportive care requirements
• Creating training materials for emergency and dermatology teams on rapid recognition

How Biotic Artlab Supports SJS and TEN Communication

We work with pharmaceutical companies, hospital systems, and patient safety organizations to create accurate, engaging visuals that make the severity and biology of SJS and TEN clear to patients, families, and clinical teams.

• Custom 3D animations of keratinocyte apoptosis and skin detachment mechanisms
• Detailed illustrations of the SJS to TEN severity spectrum
• Patient safety materials on high risk medications and early symptom recognition
• Clinical training content for emergency, dermatology, and burn care teams
• Educational visuals explaining SCORTEN and mortality risk assessment
• Conference presentations for dermatology and patient safety audiences

Frequently Asked Questions

What is the difference between SJS and TEN?

They represent different severities of the same underlying condition, classified based on how much of the body’s skin surface is affected, with TEN involving considerably more extensive skin detachment and carrying higher mortality risk than SJS.¹

Which medications most commonly cause SJS and TEN?

Allopurinol, certain anticonvulsants, sulfonamide antibiotics, and specific nonsteroidal anti inflammatory drugs are among the medications most frequently associated with triggering these conditions, though many other drugs have also been documented as occasional causes.⁴

How quickly do symptoms develop after starting a triggering medication?

Reactions typically develop within about four weeks of starting the causative medication, often beginning with nonspecific symptoms before the characteristic skin and mucosal findings appear.¹

Why is eye involvement such a significant concern with SJS and TEN?

Eye involvement can range from mild conjunctivitis to severe corneal scarring, and without prompt ophthalmologic care, survivors can experience permanent vision impairment, making eye evaluation an essential part of comprehensive treatment.³

How is mortality risk assessed in SJS and TEN?

Clinicians commonly use a scoring system called SCORTEN, calculated within the first twenty four hours of hospital admission, which incorporates several clinical factors to help estimate an individual patient’s mortality risk and guide treatment intensity.⁵

Can someone who has had SJS or TEN take the same medication again?

No. Patients who have experienced SJS or TEN should permanently avoid the responsible medication and any chemically related drugs, since reexposure carries significant risk of triggering another, potentially more severe reaction.¹

Have a Project in Mind? Contact Us.

If you are developing patient safety materials, clinical training content, or marketing visuals related to SJS, TEN, or severe drug reactions, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information, StatPearls. Stevens Johnson Syndrome and Toxic Epidermal Necrolysis.
2. National Center for Biotechnology Information. Toxic Epidermal Necrolysis, Management Issues and Treatment Options.
3. National Center for Biotechnology Information. Study of Ocular Manifestations of Stevens Johnson Syndrome and Toxic Epidermal Necrolysis.
4. National Center for Biotechnology Information. A Compilation of Drug Etiologies of Stevens Johnson Syndrome and Toxic Epidermal Necrolysis.
5. National Center for Biotechnology Information. Predictive Value of a Severity of Illness Score for Toxic Epidermal Necrolysis, SCORTEN Factors for In Hospital Mortality.
6. National Center for Biotechnology Information. Clinical Features, Outcomes and Treatment in Children With Drug Induced Stevens Johnson Syndrome and Toxic Epidermal Necrolysis.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.